Ligand efficiency indices for effective drug discovery

被引:228
作者
Abad-Zapatero, Cele [1 ,2 ]
机构
[1] Abbott Labs, Dept Biol Struct, Abbott Pk, IL 60064 USA
[2] Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA
关键词
computer-assisted drug discovery; fragment-based drug design; lead optimization; ligand efficiency indices; structure-based drug discovery;
D O I
10.1517/17460441.2.4.469
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Successful drug discovery requires the optimization of a large number of variables ranging from strictly physicochemical parameters such as molecular weight to more complex parameters related to toxicity and bioavailability. Presently, structure-based methodologies influence many aspects of the drug discovery process from lead discovery to the final preclinical characterization. However, critical biological issues along the path to the market have diminished the impact and power of this methodology. The physicochemical properties of the novel chemical entities designed and guided by structural methods have become the subject of intense scrutiny from lead discovery to drug candidate. The idea of ligand efficiency (binding energy/non-hydrogen atoms) has recently emerged as a useful guide to optimize fragment and lead selection in the discovery process. More generalized concepts of ligand efficiency, related to efficiency per dalton and per unit of polar surface area, have also been introduced and will be discussed in the broader context. Preliminary results and trends obtained using ligand efficiencies as guides are reviewed and their future application to guide drug discovery will be discussed, as well as their integration into the structure-based drug design methods to make them more effective and numerically robust.
引用
收藏
页码:469 / 488
页数:20
相关论文
共 62 条
  • [1] Ligand efficiency indices as guideposts for drug discovery
    Abad-Zapatero, C
    Metz, JT
    [J]. DRUG DISCOVERY TODAY, 2005, 10 (07) : 464 - 469
  • [2] ABADZAPATERO C, 2006, FRAGMENT BASED APPRO, P249
  • [3] The genome sequence of Drosophila melanogaster
    Adams, MD
    Celniker, SE
    Holt, RA
    Evans, CA
    Gocayne, JD
    Amanatides, PG
    Scherer, SE
    Li, PW
    Hoskins, RA
    Galle, RF
    George, RA
    Lewis, SE
    Richards, S
    Ashburner, M
    Henderson, SN
    Sutton, GG
    Wortman, JR
    Yandell, MD
    Zhang, Q
    Chen, LX
    Brandon, RC
    Rogers, YHC
    Blazej, RG
    Champe, M
    Pfeiffer, BD
    Wan, KH
    Doyle, C
    Baxter, EG
    Helt, G
    Nelson, CR
    Miklos, GLG
    Abril, JF
    Agbayani, A
    An, HJ
    Andrews-Pfannkoch, C
    Baldwin, D
    Ballew, RM
    Basu, A
    Baxendale, J
    Bayraktaroglu, L
    Beasley, EM
    Beeson, KY
    Benos, PV
    Berman, BP
    Bhandari, D
    Bolshakov, S
    Borkova, D
    Botchan, MR
    Bouck, J
    Brokstein, P
    [J]. SCIENCE, 2000, 287 (5461) : 2185 - 2195
  • [4] Scaffold oriented synthesis. Part 1: Design, preparation, and biological evaluation of thienopyrazoles as kinase inhibitors
    Akritopoulou-Zanze, I
    Darczak, D
    Sarris, K
    Phelan, KM
    Huth, JR
    Song, DY
    Johnson, EF
    Jia, Y
    Djuric, SW
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (01) : 96 - 99
  • [5] 2-(Oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases
    Andersen, HS
    Iversen, LF
    Jeppesen, CB
    Branner, S
    Norris, K
    Rasmussen, HB
    Moller, KB
    Moller, NPH
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (10) : 7101 - 7108
  • [6] The properties of known drugs .1. Molecular frameworks
    Bemis, GW
    Murcko, MA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) : 2887 - 2893
  • [7] The Protein Data Bank
    Berman, HM
    Westbrook, J
    Feng, Z
    Gilliland, G
    Bhat, TN
    Weissig, H
    Shindyalov, IN
    Bourne, PE
    [J]. NUCLEIC ACIDS RESEARCH, 2000, 28 (01) : 235 - 242
  • [8] Blaney J., 2006, FRAGMENT BASED APPRO, P215
  • [9] Science, art and drug discovery: a personal perspective
    Campbell, SF
    [J]. CLINICAL SCIENCE, 2000, 99 (04) : 255 - 260
  • [10] Fragment-based lead discovery: leads by design
    Carr, RAE
    Congreve, M
    Murray, CW
    Rees, DC
    [J]. DRUG DISCOVERY TODAY, 2005, 10 (14) : 987 - 992